Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Emerging Targeted and Immune-Based Therapies in Sarcoma.

Pollack SM, Ingham M, Spraker MB, Schwartz GK.

J Clin Oncol. 2017 Dec 8:JCO2017751610. doi: 10.1200/JCO.2017.75.1610. [Epub ahead of print]

PMID:
29220291
2.

Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery.

Fontecilla NM, Kittler NW, Geskin L, Samie FH, Niedt G, Imahiyerobo T, Schwartz G, Ingham M, Lewin JM.

JAAD Case Rep. 2017 Sep 23;3(6):467-469. doi: 10.1016/j.jdcr.2017.06.019. eCollection 2017 Nov. No abstract available.

3.

The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis.

Cameron C, Ewara E, Wilson FR, Varu A, Dyrda P, Hutton B, Ingham M.

Med Decis Making. 2017 Nov;37(8):894-904. doi: 10.1177/0272989X17711933. Epub 2017 Jun 16.

PMID:
28622083
4.

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.

Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS.

BMC Endocr Disord. 2017 Jun 8;17(1):32. doi: 10.1186/s12902-017-0180-8.

5.

Cell-Cycle Therapeutics Come of Age.

Ingham M, Schwartz GK.

J Clin Oncol. 2017 Sep 1;35(25):2949-2959. doi: 10.1200/JCO.2016.69.0032. Epub 2017 Jun 3. Review.

PMID:
28580868
6.

Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.

Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L.

Patient Prefer Adherence. 2017 May 18;11:947-958. doi: 10.2147/PPA.S133222. eCollection 2017.

7.

Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.

Kariburyo MF, Xie L, Teeple A, Tan H, Ingham M.

Adv Ther. 2017 Jun;34(6):1398-1410. doi: 10.1007/s12325-017-0545-4. Epub 2017 May 8.

8.

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis.

Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP.

Patient Prefer Adherence. 2017 Mar 28;11:661-669. doi: 10.2147/PPA.S121032. eCollection 2017.

9.

Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.

Buysman EK, Anderson A, Bacchus S, Ingham M.

Adv Ther. 2017 Apr;34(4):937-953. doi: 10.1007/s12325-017-0500-4. Epub 2017 Mar 1.

PMID:
28251556
10.

Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis.

Tkacz J, Ingham MP, Brady BL, Meyer R, Ruetsch C.

Am Health Drug Benefits. 2015 Dec;8(9):494-505.

11.

Targeting Medication Non-Adherence Behavior in Selected Autoimmune Diseases: A Systematic Approach to Digital Health Program Development.

van Mierlo T, Fournier R, Ingham M.

PLoS One. 2015 Jun 24;10(6):e0129364. doi: 10.1371/journal.pone.0129364. eCollection 2015. Review.

12.

Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders.

Kozma CM, Ingham M, Paris A, Ellis L.

J Med Econ. 2015;18(8):646-53. doi: 10.3111/13696998.2015.1035278. Epub 2015 Apr 24.

PMID:
25830699
13.

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators.

Respir Res. 2013 Jul 13;14:73. doi: 10.1186/1465-9921-14-73.

14.

Microarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor.

Llorens F, Hummel M, Pantano L, Pastor X, Vivancos A, Castillo E, Mattlin H, Ferrer A, Ingham M, Noguera M, Kofler R, Dohm JC, Pluvinet R, Bayés M, Himmelbauer H, del Rio JA, Martí E, Sumoy L.

BMC Genomics. 2013 Jun 1;14:371. doi: 10.1186/1471-2164-14-371.

15.

Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer.

Lambert JW, Ingham M, Gibbs BB, Given RW, Lance RS, Riggs SB.

Urology. 2013 Mar;81(3):587-92. doi: 10.1016/j.urology.2012.10.055. Epub 2013 Jan 24.

PMID:
23352372
16.

Comparative multidatabase analysis of dosing patterns and infusion intervals for the first 12 infliximab infusions in patients with rheumatoid arthritis.

Bolge SC, Carter CT, Mueller CS, Bailey RA, Ingham MP.

Clin Ther. 2012 Dec;34(12):2286-92. doi: 10.1016/j.clinthera.2012.10.010. Epub 2012 Nov 13.

17.

Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis.

Llorens F, Hummel M, Pastor X, Ferrer A, Pluvinet R, Vivancos A, Castillo E, Iraola S, Mosquera AM, González E, Lozano J, Ingham M, Dohm JC, Noguera M, Kofler R, del Río JA, Bayés M, Himmelbauer H, Sumoy L.

BMC Genomics. 2011 Jun 23;12:326. doi: 10.1186/1471-2164-12-326.

18.

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW.

N Engl J Med. 2010 Aug 12;363(7):620-8. doi: 10.1056/NEJMoa1002110. Epub 2010 May 18.

19.

Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.

McGarry LJ, Merchant S, Nathwani D, Pawar V, DeLong K, Thompson D, Akhras K, Ingham M, Weinstein MC.

J Med Econ. 2010 Mar;13(1):142-7. doi: 10.3111/13696991003604108.

PMID:
20136579
20.

Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein.

Looze C, Yui D, Leung L, Ingham M, Kaler M, Yao X, Wu WW, Shen RF, Daniels MP, Levine SJ.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):433-8. doi: 10.1016/j.bbrc.2008.11.050. Epub 2008 Nov 24.

Supplemental Content

Loading ...
Support Center